Share on StockTwits

POZEN (NASDAQ:POZN) VP John E. Barnhardt sold 77,840 shares of the company’s stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $8.31, for a total value of $646,850.40. Following the completion of the sale, the vice president now directly owns 42,321 shares in the company, valued at approximately $351,688. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on POZN. Analysts at TheStreet upgraded shares of POZEN from a “sell” rating to a “hold” rating in a research note on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $9.92.

Shares of POZEN (NASDAQ:POZN) traded down 0.24% during mid-day trading on Friday, hitting $8.38. 161,001 shares of the company’s stock traded hands. POZEN has a 52 week low of $4.73 and a 52 week high of $9.90. The stock has a 50-day moving average of $8.49 and a 200-day moving average of $8.17. The company’s market cap is $258.6 million.

POZEN (NASDAQ:POZN) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.04) by $0.13. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $5.50 million. During the same quarter last year, the company posted ($0.19) earnings per share. POZEN’s revenue was up 433.5% compared to the same quarter last year. On average, analysts predict that POZEN will post $0.58 earnings per share for the current fiscal year.

POZEN Inc (NASDAQ:POZN), is a pharmaceutical company focused on transforming medicine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.